Semaglutide

Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of type 2 diabetes and chronic weight management. It stimulates insulin secretion and signals to the brain to reduce appetite and caloric intake.

API suppliers (6)

Suppliers of Semaglutide backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD2 active DMF
• YANGZHOU LIBERTY PHARMACEUTICAL CO LTDChina2 active DMF
• FUJIAN GENOHOPE BIOTECH LTDChina2 active DMF
• SUZHOU VDOBIOTECH CO LTD2 active DMF
• SICHUAN FRONTIER BIOPHARMACEUTICAL CO LTD2 active DMF
• ZHEJIANG PEPTITES BIOTECH CO LTD2 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (27 approved US products), the latest listed US patent on Semaglutide expires 17 Feb 2041 and exclusivity 19 Mar 2029. Generic API sourcing typically opens up once these lapse.

Therapeutic areas